Maria José Terol (María José Terol, Maria Jose Terol, Maria J Terol)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Iron Deficiency

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Alejandro Martin Martin Garcia-Sancho, Ranjana Advani, Jose Maria Roncero Vidal, Raquel de Oña Navarrete, Ana Marín-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood advances 8 (17) (2024)
Beatriz Rey Búa, Carlos Grande, Jose Javier Sánchez Blanco, Pau Abrisqueta, Antonio Gutierrez, Ángel R Payer, Eva Giné, Izaskun Zeberio Etxetxipia, Maria José Terol, Fátima de la Cruz Vicente, Rafael Andreu, María José Ramírez, Adolfo de la Fuente, María Cruz Viguria, María Jesus Peñarrubia, Ana Jiménez-Ubieto, Santiago Montes Moreno, Armondo López-Guillermo, María Dolores Caballero, Alejandro Martin Martin Garcia-Sancho
Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Beatriz Rey Búa, Carlos Grande, Jose Javier Sánchez Blanco, Pau Abrisqueta, Antonio Gutierrez, Ángel R Payer, Eva Giné, Izaskun Zeberio Etxetxipia, Maria José Terol, Fátima de la Cruz Vicente, Rafael Andreu, María José Ramírez, Adolfo de la Fuente, María Cruz Viguria, María Jesus Peñarrubia, Ana Jiménez-Ubieto, Santiago Montes Moreno, Armondo López-Guillermo, María Dolores Caballero, Alejandro Martin Martin Garcia-Sancho
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (17) (2024)
Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz, Alejandro Martin Martin Garcia-Sancho, Ranjana H Advani, Josep Maria Roncero Vidal, Raquel De Oña, Ana Marin-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma. Blood advances (2024)
Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Alejandro Martin Martin Garcia-Sancho, Ranjana Advani, Jose Maria Roncero Vidal, Raquel de Oña Navarrete, Ana Marín-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood advances 8 (17) (2024)